Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Pirtskhalaishvili, G.
  • Shurin, G. V.
  • Gambotto, A.
  • Esche, C.
  • Wahl, M.
  • Yurkovetsky, Z. R.
  • Robbins, Paul D.
  • Shurin, M. R.

publication date

  • August 2000

journal

  • Journal of Immunology  Journal

abstract

  • We have shown that prostate cancer (PCa) causes apoptosis of dendritic cells (DC), which might block the development of specific antitumor immune responses. Analysis of murine prostatic carcinoma tissues revealed the significant decrease in intratumoral DC number during tumor progression. We demonstrated that the cytokine-mediated increase in DC survival was accompanied by an elevated expression of the anti-apoptotic protein Bcl-xL. Next, we evaluated the resistance to tumor-induced apoptosis and the antitumor efficiency of genetically engineered DC overexpressing Bcl-xL. DC were transduced with an adenoviral vector encoding the murine Bcl-xL gene and injected intratumorally. Data analysis revealed that treatment of PCa-bearing mice with Bcl-xL-transduced DC resulted in significant inhibition of tumor growth compared with the administration of nontransduced DC. Thus, our data suggest that the protection of DC from PCa-induced apoptosis might significantly increase the efficacy of DC-based therapies in cancer even in the absence of available tumor-specific Ags.

subject areas

  • Animals
  • Antigens, CD95
  • Antineoplastic Agents
  • Apoptosis
  • Cell Count
  • Cell Movement
  • Cell Survival
  • Cells, Cultured
  • Dendritic Cells
  • Disease Progression
  • Fas Ligand Protein
  • Gene Expression Regulation
  • Genetic Vectors
  • Growth Inhibitors
  • Humans
  • Immunity, Innate
  • Injections, Intralesional
  • Interleukin-12
  • Ligands
  • Male
  • Membrane Glycoproteins
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Inbred MRL lpr
  • Neoplasm Transplantation
  • Prostatic Neoplasms
  • Proto-Oncogene Proteins c-bcl-2
  • Transfection
  • Tumor Cells, Cultured
  • bcl-X Protein
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0022-1767

PubMed ID

  • 10925278
scroll to property group menus

Additional Document Info

start page

  • 1956

end page

  • 1964

volume

  • 165

issue

  • 4

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support